Briacell Therapeutics Corp., of Berkeley, Calif. and Vancouver, British Columbia, said it has completed development of a new frozen formulation of its lead candidate, the cellular immunotherapy Bria-IMT. The new formulation will enable on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs vs. the old formulation, the company said.